The U.S. National Institute of Allergy and Infectious Diseases has reportedly exercised options to conduct Phase 1 human-safety trials and non-human primate efficacy studies of an intramuscular formulation of BioCryst Pharmaceuticals’ BCX4430 to advance its development as a treatment for hemorrhagic fever viruses such as Ebola. The options will provide an additional $4.1 million to the Research Triangle Park-based company as part of a September 2013 grant valued up to $22 million over five years if all options are exercised.
BioCryst Chief Medical Officer William Sheridan said, “The ongoing Ebola epidemic in West Africa emphasizes the urgent need for safe and effective antiviral agents for hemorrhagic fever virus diseases. We look forward to the body of evidence supporting BCX4430 evolving into a highly compelling package, enabling us to attract U.S. government advanced development funding. This is critical so that a new drug application can be filed as quickly as feasible for this unique, broad spectrum antiviral.” See BioCryst Pharmaceuticals, Inc. Press Release, August 13, 2014.